Venture cash funds first human trials
Private company trial initiations stand out in the latest week’s disclosures.
CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
ASCO-GU – Corbus throws its hat into the Nectin-4 ring
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
